

ONE HUNDRED EIGHTH LEGISLATURE - SECOND SESSION - 2024
COMMITTEE STATEMENT
LB795

Hearing Date: Friday February 24, 2023
Committee On: Judiciary
Introducer: Wayne
One Liner: Provide immunity for administration of naloxone or other federally approved opioid antagonists

Roll Call Vote - Final Committee Action:
Advanced to General File

Vote Results:

Aye: 8 Senators Blood, Bosn, DeBoer, DeKay, Holdcroft, Ibach, McKinney, Wayne
Nay:
Absent:
Present Not Voting:

Testimony:

Proponents:

Senator Justin Wayne
Matthew Welsh
Amy Holman

Representing:

Opening Presenter
Opiant
Nebraska Pharmacists Association

Opponents:

Representing:

Neutral:

Representing:

* ADA Accommodation Written Testimony

Summary of purpose and/or changes:

Currently, Section 28-470 provides immunity for the administration of naloxone under certain circumstances. LB795 amends Section 28-470 to replace each use of the word "naloxone" with the term "opioid antagonist," which is defined to include naloxone and any other FDA-approved method of reversing an opioid overdose.

Justin Wayne, Chairperson

